Results 51 to 60 of about 14,668 (165)
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain +13 more
doaj +1 more source
Summary Myeloma bone disease (MBD) affects ~90% of myeloma patients, causing pain and reduced quality of life. Current anti‐resorptive treatments retard further destruction but do not repair bone. As new myeloma therapies emerge, understanding their impact on MBD is crucial.
Rebecca E. Andrews +7 more
wiley +1 more source
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source
Daratumumab bewährt sich in der Rezidivtherapie
Die aktualisierte Auswertung der Phase-III-Studie POLLUX untermauert den anhalten-den Benefit von Daratumumab zusätzlich zu Lenalidomid/Dexamethason (Rd) bei Patientien mit rezidiviertem oder refraktärem MM (rrMM): Durch die Daratumumab-Addition werden ...
Katharina Arnheim
core +1 more source
Background Daratumumab represents the first‐in‐class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM).
Oscar C. Y. Yang +7 more
doaj +1 more source
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez +3 more
doaj +1 more source
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos +18 more
doaj +1 more source
Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto +24 more
wiley +1 more source
ABSTRACT Objectives The MYLENE non‐interventional study (NIS) aimed to close the gap in real‐world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non‐transplant eligible multiple myeloma in Germany.
Eyck von der Heyde +9 more
wiley +1 more source
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens +13 more
doaj +1 more source

